February 2024

UROLOGY

JOSHUA J. MEEKS, MD, PHD, TALKS BCG SHORTAGE AND NADOFARAGENE FIRADENOVEC WITH UROTODAY

Featuring: Joshua J. Meeks, MD, PhD
​
In two UroToday videos, Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD Professor of Urology at Northwestern Medicine, weighs in on timely topics such as the BCG shortage and using nadofaragene firadenove to treat BCG-unresponsive bladder cancer.
​
​Dr. Meeks on the BCG Shortage

This UroToday interview highlights the ongoing BCG shortage in bladder cancer treatment, which initially saw production shortages in 2012. Dr. Meeks highlights the use of gemcitabine-docetaxel as an effective and available alternative for high-risk bladder cancer. Additionally, he discusses the BRIDGE trial and significant trials by AstraZeneca, Merck and Pfizer, which are exploring checkpoint inhibitors as potential BCG alternatives.

Watch Dr. Meeks’ interview on UroToday > 

Dr. Meeks on Nadofaragene Firadenovec

In another UroToday video, Dr. Meeks discusses the role of nadofaragene firadenovec in treating BCG-unresponsive bladder cancer with Sam Chang, MD, MBA. They highlight the significance of clinical trials and FDA approval for nadofaragene, as well as the strong patient interest in this new treatment option. Dr. Meeks explains the challenges with current therapies, such as dual chemotherapy and pembrolizumab, and emphasizes the potential benefits of nadofaragene, including its efficacy and quarterly dosing.

They both stress the importance of patient education about the benefits and side effects of nadofaragene, expressing cautious optimism about this nonsurgical option.

Watch the video to learn more >

​
Joshua J. Meeks, MD, PhD the Edward M. Schaeffer, MD, PhD Professor of Urology and a Northwestern Medicine Urologist

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like